Home » Topics » Conferences

Conferences
RSS

Org-23366: an atypical antipsychotic potentially superior to clozapine

Aug. 23, 1999

ACS news: Wyeth-Ayerst investigates agents for urinary incontinence

Aug. 23, 1999

Phase II results validate Emisphere's technology for oral delivery of heparin

Aug. 23, 1999

Preclinical profile of rPSGL-Ig indicates clinical testing is warranted

Aug. 23, 1999

Dual TP antagonist/TxA2 synthase inhibitor presented by Servier

Aug. 23, 1999

WHI-P164, a potential treatment for atherosclerosis in patients with hyperlipidemia, hypertension

Aug. 23, 1999

Servier's novel approach to antiplatelet therapy: dual TP antagonists/NO donors

Aug. 20, 1999

Factor Xa inhibitor HMR-2906 is more effective and safer than hirudin in dog model of thrombosis

Aug. 20, 1999

Sanofi researchers modify heparin structure to improve on therapeutic properties

Aug. 20, 1999

RWJ-56110: first report of a new antithrombotic targeting the PAR-1 receptor

Aug. 20, 1999

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 22, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 23, 2026.
Cell/gene therapy sector now sustainable; China competition mounting
BioWorld
There was an upbeat message for cell and gene therapy companies in the 2026 industry update presented as the J.P. Morgan Healthcare Conference opened on Monday,...
Neurotrimin unveiled as marker in intellectual disability
BioWorld Science
Neurotrimin (NTM) is a member of the IgLON family, the disruption of which has been tied to emotional learning deficits and anxiety-like behavior in animal...
Abbvie snags PD-1/VEGF bispecific in potential $5B Remegen deal
BioWorld
With rumors regarding a couple of potential mega-mergers making the rounds, the week of the annual J.P. Morgan Healthcare Conference kicked off with the official...